Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Mental Health Borderline Personality Disorder

Psychedelics could make mental health worse in people with a personality disorder

by Pouya Movahed Rad
May 4, 2024
in Borderline Personality Disorder, Psychedelic Drugs
Share on TwitterShare on Facebook

The interest in psychedelics is growing both in scientific circles and among the public. These are powerful substances capable of altering perception, mood and various mental processes. They also show promise for treating a wide range of mental health disorders.

However, for their use to be safe and effective, it’s important to understand how they interact with different mental health conditions. This is especially true for personality disorders.

A personality disorder is a type of mental disorder involving rigid and unhealthy patterns of thinking, functioning and behaving, which significantly affect a person’s life. Understanding their interaction with psychedelics is crucial. These substances can deeply influence mental states. They can worsen or improve symptoms in ways unique to these disorders.

In a recent study, researchers at Imperial College London investigated the complex relationship between psychedelics and mental health, highlighting the potential risks for people with personality disorders.

The study collected self-reported data from 807 people who used psychedelics in various settings, from recreational to therapeutic. They measured participants’ mental wellbeing before and after using psychedelics using a scale called the Warwick-Edinburgh mental wellbeing scale. The researchers considered it a meaningful drop in mental health if someone’s happiness and wellbeing fell more than what was typical for most people in the study.

The researchers specifically looked at those who had negative experiences while on psychedelics. They found that only 16% of all participants reported an overall negative response. But a significant portion of these negative experiences (31%) were reported by people with a history of personality disorders.

However, the study has several limitations, including the reliance on self-reported data, the small number of participants and a 56% dropout rate. All of these factors would have skewed the results.

Other limitations include the lack of a control group (people given a placebo or standard treatment) for comparison. Additionally, there were variations in the types and dosages of psychedelics used.

Google News Preferences Add PsyPost to your preferred sources

The study’s method of participant selection could also lead to biased results. And lumping different personality disorders together might overlook specific risks associated with each.

Different responses

Various personality disorders might respond differently to psychedelics. For instance, people with histrionic personality disorder (excessive attention-seeking and emotional overreaction) or borderline personality disorder (emotional instability, intense relationships and fear of abandonment) might feel worse or more unstable.

And those with schizotypal personality disorder (social anxiety, odd beliefs and eccentric behaviour) could become more paranoid.

People with narcissistic personality disorder (excessive self-importance, lack of empathy, and need for admiration) may struggle with the self-reflective nature of psychedelics because they often have a hard time handling criticism.

Considering the study’s notable limitations, we must approach its findings with some scepticism. Yet the study does recognise the potential benefits of psychedelics for mental health, stressing the need for careful screening for personality disorders.

Using psychedelics safely and effectively requires a personalised approach. This is especially true for vulnerable people. This highlights the importance of refining psychedelic therapy to make it safe and effective for all.

As we explore the expanding territory of psychedelic therapy, it’s vital to understand how these substances interact with mental health conditions – including personality disorders.

We must use more rigorous methods, such as controlled trials to compare psychedelics to standard treatments or a placebo. Personality disorders should also be verified via professional evaluation, not just self-reports. And, finally, psychedelic doses need to be uniform in order to reliably assess their therapeutic effect.The Conversation

 

This article is republished from The Conversation under a Creative Commons license. Read the original article.

RELATED

The surprising way the brain’s dopamine-rich reward center adapts as a romance matures
Borderline Personality Disorder

Borderline personality disorder in youth linked to altered brain activation during self-identity processing

February 7, 2026
Lifetime ecstasy use is associated with lower odds of impairments in social functioning, study finds
MDMA

Recreational ecstasy use is linked to lasting memory impairments

February 6, 2026
One specific reason for having sex is associated with higher stress levels the next day
Psilocybin

Psilocybin impacts immunity and behavior differently depending on diet and exercise context

February 4, 2026
Surprising link found between hyperthyroidism and dark personality traits
Depression

Long-term antidepressant effects of psilocybin linked to functional brain changes

January 31, 2026
A dream-like psychedelic might help traumatized veterans reset their brains
Psychedelic Drugs

A dream-like psychedelic might help traumatized veterans reset their brains

January 30, 2026
Major new study finds psilocybin microdoses improve the quality of creative ideas but not the quantity
Microdosing

Major new study finds psilocybin microdoses improve the quality of creative ideas but not the quantity

January 24, 2026
Could MDMA offer new hope for borderline personality disorder treatment?
Depression

MDMA-assisted therapy shows promise for long-term depression relief

January 20, 2026
Does psilocybin really provide long-term relief from depression, as new study suggests?
Microdosing

Psilocybin microdosing fails to boost cognitive performance in rigorous trials

January 19, 2026

PsyPost Merch

STAY CONNECTED

LATEST

Evolutionary psychology’s “macho” face ratio theory has a major flaw

Reduction in PTSD symptoms linked to better cognitive performance in new study of veterans

Scientists reveal the alien logic of AI: hyper-rational but stumped by simple concepts

Self-kindness leads to a psychologically rich life for teenagers, new research suggests

Borderline personality disorder in youth linked to altered brain activation during self-identity processing

Biological sex influences how blood markers reflect Alzheimer’s severity

The surprising way the brain’s dopamine-rich reward center adapts as a romance matures

The scientist who predicted AI psychosis has issued another dire warning

RSS Psychology of Selling

  • Sales agents often stay for autonomy rather than financial rewards
  • The economics of emotion: Reassessing the link between happiness and spending
  • Surprising link found between greed and poor work results among salespeople
  • Intrinsic motivation drives sales performance better than financial rewards
  • New research links faking emotions to higher turnover in B2B sales
         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy